Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Pimecrolimus 0.3% ophthalmic ointment for blepharitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blepharitis

Drugs mentioned

• Pimecrolimus 0.3% Ophthalmic Ointment (pimecrolimus)

Snippet

Sponsor: Famy Life Sciences, a Viatris Company | Conditions: Blepharitis | Phase 3 | Status: TERMINATED